We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+14.79%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$219M
AUM Growth
-$94M
Cap. Flow
-$113M
Cap. Flow %
-51.44%
Top 10 Hldgs %
66.53%
Holding
66
New
5
Increased
5
Reduced
14
Closed
42

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$11.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$9.93M
3
LEGN icon
Legend Biotech
LEGN
+$6.48M
4
ARGX icon
argenx
ARGX
+$4.58M
5
ABBV icon
AbbVie
ABBV
+$3.39M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$28.9M
2
DXCM icon
DexCom
DXCM
+$24.9M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$19.3M
4
WST icon
West Pharmaceutical
WST
+$8.42M
5
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$8.04M

Sector Composition

Rank Sector Weight
1 Healthcare 93.12%
2 Consumer Staples 0%
3 Energy 0%
4 Financials 0%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
26
Amgen
AMGN
$210B
– –
-107,480
Closed -$28.9M
AMLX icon
27
Amylyx Pharmaceuticals
AMLX
$2.24B
– –
-282,862
Closed -$5.18M
APH icon
28
Amphenol
APH
$201B
– –
-5,164
Closed -$217K
DOC icon
29
Healthpeak Properties
DOC
$14.9B
– –
-10,215
Closed -$188K
DXCM icon
30
DexCom
DXCM
$32.9B
– –
-267,380
Closed -$24.9M
EDIT icon
31
Editas Medicine
EDIT
$407M
– –
-19,295
Closed -$151K
ELV icon
32
Elevance Health
ELV
$83B
– –
-568
Closed -$247K
ETNB
33
DELISTED
89bio
ETNB
– –
-249,571
Closed -$3.85M
FAST icon
34
Fastenal
FAST
$55.2B
– –
-7,328
Closed -$200K
GCMG icon
35
GCM Grosvenor
GCMG
$795M
– –
-10,229
Closed -$79.4K
GERN icon
36
Geron
GERN
$821M
– –
-381,081
Closed -$808K
GKOS icon
37
Glaukos
GKOS
$10.1B
– –
-56,230
Closed -$4.23M
HIG icon
38
Hartford Financial Services
HIG
$39.2B
– –
-3,500
Closed -$248K
HSY icon
39
Hershey
HSY
$35.7B
– –
-1,020
Closed -$204K
IRWD icon
40
Ironwood Pharmaceuticals
IRWD
$728M
– –
-10,326
Closed -$99.4K
ISRG icon
41
Intuitive Surgical
ISRG
$130B
– –
-8,353
Closed -$2.44M
ITW icon
42
Illinois Tool Works
ITW
$83B
– –
-932
Closed -$215K
JBLU icon
43
JetBlue
JBLU
$2.35B
– –
-14,952
Closed -$68.8K
KVUE icon
44
CALL
Kenvue
KVUE
$36.5B
– –
-55,000
Closed -$1.1M
NMRK icon
45
Newmark Group
NMRK
$2.72B
– –
-11,417
Closed -$73.4K
NUVL
46
DELISTED
Nuvalent
NUVL
– –
-113,528
Closed -$5.22M
PMVP icon
47
PMV Pharmaceuticals
PMVP
$59.7M
– –
-821,384
Closed -$5.04M
PSEC icon
48
Prospect Capital
PSEC
$1.1B
– –
-27,957
Closed -$169K
RES icon
49
RPC Inc
RES
$1.28B
– –
-12,071
Closed -$108K
RXRX icon
50
Recursion Pharmaceuticals
RXRX
$1.76B
– –
-22,471
Closed -$172K
1
2
3

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Tri Locum Partners held 66 positions worth $219M, down 30% from $313M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Tri Locum Partners withdrew a net $113M in Q4 2023, closing 42 positions and reducing 14 holdings. Its most notable exit was Amgen, an estimated $28.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Energy.

Against the trend, Tri Locum Partners opened a new position in Biogen worth $11.9M.

  • Tri Locum Partners's largest Q4 2023 buy was Biogen: 45,814 shares worth $11.9M.
  • Tri Locum Partners added most to argenx in Q4 2023, an estimated $4.58M increase.
  • Tri Locum Partners's biggest Q4 2023 reduction was Teva Pharmaceuticals, cutting an estimated $7.83M.
  • Tri Locum Partners fully exited Amgen in Q4 2023, selling an estimated $28.9M.
  • Tri Locum Partners's ten largest holdings make up 67% of its $219M portfolio in Q4 2023.
  • Tri Locum Partners opened 5 new positions and closed 42 in Q4 2023.
  • Tri Locum Partners's portfolio value fell 30% quarter-over-quarter to $219M.

Based on Tri Locum Partners's 13F filing for Q4 2023, filed 14 Feb 2024.